Isis, Genzyme cholesterol drug to face one-year delay

The FDA has asked for more clinical trial data on cancer risk linked to mipomersen, a cholesterol treatment Isis Pharmaceuticals and Genzyme Corp. are working on, delaying regulatory approval for at least one year. The drugmakers said they will accelerate plans to conduct an outcomes study based on agency guidance in parallel with ongoing trials of the drug, which is intended to treat homozygous familial hypercholesterolemia.

View Full Article in:

Boston Globe (tiered subscription model), The · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Director of Operations - GBS
Mayo Clinic
Rochester, MN
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Senior Vice President, Clinical Affairs & Strategic Partnerships
America's Health Insurance Plans (AHIP)
Washington, DC